Three-month comparison of bimatoprost and latanoprost in patients with glaucoma and ocular hypertension

Advances in Therapy

Volumn 18, Issue 3, 2001, Pages 110-121

  Gandolfi, S ^a   Simmons, S T ^b   Sturm, R ^c   Chen, K ^d   VanDenburgh, A M ^d  

^a UNIVERSITY OF PARMA   (Italy)

^b Glaucoma Consultants of the Capital Region   (United States)

^c OPHTHALMIC CONSULTANTS OF LONG ISLAND   (United States)

^d ALLERGAN INC   (United States)

Author keywords

Bimatoprost; Glaucoma; Intraocular pressure; Latanoprost; Ocular hypertension

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIMATOPROST; CARBONATE DEHYDRATASE INHIBITOR; DORZOLAMIDE; LATANOPROST; PROSTAGLANDIN DERIVATIVE; TIMOLOL; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; EYE IRRITATION; FEMALE; GLAUCOMA; HEADACHE; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; IRITIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; RETINA MACULA CYSTOID EDEMA; UVEITIS; VISUAL ACUITY;

AMIDES; ANTIHYPERTENSIVE AGENTS; DOUBLE-BLIND METHOD; FEMALE; GLAUCOMA; HUMANS; INTRAOCULAR PRESSURE; LIPIDS; MALE; MIDDLE AGED; OCULAR HYPERTENSION; PROSTAGLANDINS F, SYNTHETIC;

EID: 0034850210     PISSN: 0741238X     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02850299     Document Type: Article

References (13)

1. The pharmacology of bimatoprost (Lumigan™)
2. 6-Month comparison of bimatoprost once-daily, and twice-daily with timolol twice-daily in patients with elevated IOP
3. Efficacy and safety of bimatoprost in patients with elevated IOP: A 30-day comparison with latanoprost
4. A useful testing strategy in phase II trials: Combined test of superiority and test of equivalence
5. The relationship between control of intraocular pressure and visual field deterioration
6. Intraocular pressure-dependent progression of visual field loss in advanced primary open-angle glaucoma: A 15-year follow-up
7. Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures
8. Effect of timolol, latanoprost, and dorzolamide on circadian IOP in glaucoma or ocular hypertension
9. Large diurnal fluctuations in intraocular pressure are an independent risk factor in patients with glaucoma
10. Fluctuations of intraocular pressure during the day in open-angle glaucoma, normal-tension glaucoma and normal subjects
11. Presence and rapid decline of early morning intraocular pressure peaks in glaucoma patients
12. The incidence and time-course of latanoprost-induced iridial pigmentation as a function of eye color
13. Migraine headache associated with latanoprost